Baylor College of Medicine

St. Baldrick's Foundation Allocates $1.1 Million for Fellowships to Empower Emerging Childhood Cancer Researchers

Retrieved on: 
Friday, March 8, 2024
Neoplasm, Cancer, Survivor, Toxicity, Osteosarcoma, Immunotherapy, Children's Hospital of Philadelphia, University, University of California, Canadian Aviation Regulations, Hospital, Brain, Child, Food, Vaccine, Cell adhesion, Bone marrow, Dana–Farber Cancer Institute, Leukemia, Medicine, Baylor College of Medicine, Acute myeloid leukemia, Food security, Lymphoma, Research, Baylor University, Immune system

The St. Baldrick's Foundation granted over $1.1 million in Fellow awards to nurture emerging childhood cancer researchers dedicated to overcoming pediatric cancers.

Key Points: 
  • The St. Baldrick's Foundation granted over $1.1 million in Fellow awards to nurture emerging childhood cancer researchers dedicated to overcoming pediatric cancers.
  • The $1.1 million was distributed to seven researchers making strides in discovering new cures for pediatric cancers.
  • The St. Baldrick's Foundation 2024 Fellows are:
    Dr. Vanja Cabric at Memorial Sloan Kettering Cancer Center, New York, NY
    Hepatoblastoma, common in childhood, lacks effective immunotherapy due to limited understanding of pediatric immune response to tumors.
  • Since 2005, St. Baldrick's has granted more than $342 million to support the development of childhood cancer treatments that have the potential to impact every kid diagnosed with cancer.

BRAINBox Solutions to Present Updated Data at Three Leading Conferences from HeadSMART II and NIH-funded Geriatrics Clinical Trials of BRAINBox TBI Concussion Test

Retrieved on: 
Monday, March 4, 2024
Doctor of Philosophy, Concussion, Emergency, TBI, Poster, Diagnosis, Bangladesh Technical Education Board, School, Alzheimer's disease, Algorithm, Geriatrics, NIH, Emergency medicine, FESC, FACC, Brainbox, Trauma, FACEP, Traumatic brain injury, ATE, Conference, Prognosis, Biomarker, Clinical trial, Serum, Medical school, Blood, Risk, Patient, Baylor College of Medicine, Update, Parkinson's disease, Medical device

RICHMOND, Va., March 4, 2024 /PRNewswire/ -- BRAINBox Solutions today announced current and upcoming presentations of clinical trends and data at three leading, upcoming medical conferences from the HeadSMART II pivotal trial in adult patients and the National Institutes of Health (NIH) funded clinical trial in geriatric patients of its BRAINBox TBI™ concussion diagnostic and prognostic test.  Concussion is also known as ATE (Acute Traumatic Encephalopathy) or mTBI (mild traumatic brain injury).

Key Points: 
  • The presentation title is, "Biomarker Profiles Distinguish Geriatric Acute TBI from Dementias:  Results from the HeadSMARTII Geriatric Feasibility Study.
  • "  The poster title is: "Biomarker Profiles Distinguish Geriatric TBI from Dementias:  Results From the HeadSMART Geriatric Feasibility Study."
  • "These presentations highlight the breadth of clinical data being assembled to evaluate the diagnostic and prognostic potential of the BRAINBox TBI test across a spectrum of age groups.
  • "These two trials have made substantial progress, as enrollment in both is expanding and, in the case of HeadSMART II, almost completed," said Donna Edmonds, BRAINBox Solutions' CEO.

American Brain Tumor Association Announces New Board of Directors Officers and Members

Retrieved on: 
Tuesday, February 27, 2024
International law, Prostate cancer, Candel, Cancer, Hospital, IPO, Doctor of Philosophy, Partner, Therapy, Texas Children's Hospital, Patient, ABTA, Baylor College of Medicine, American Brain Tumor Association, Harvard Medical School, Brain, Research, Boston Children's Hospital

CHICAGO, Feb. 27, 2024 /PRNewswire/ -- The American Brain Tumor Association announced today the appointment of officers and new members to serve as the Board of Directors.

Key Points: 
  • CHICAGO, Feb. 27, 2024 /PRNewswire/ -- The American Brain Tumor Association announced today the appointment of officers and new members to serve as the Board of Directors.
  • They will advance the ABTA mission under the leadership of Ram Subramanian, Board Chair, and Ralph DeVitto, President and CEO.
  • "Over the past year, the American Brain Tumor Association has experienced tremendous growth, demonstrating the impact of our board's vision and commitment," DeVitto said.
  • The 2024 ABTA Board of Directors Officers and Members:

Dallas Dermatology Partners Named Among D Magazine's 2023 Best Doctors

Retrieved on: 
Wednesday, February 21, 2024
University of Texas System, Private practice, Skin cancer, Psoriasis, Acne, Multimedia, Moses Austin, D Magazine, Education, University, Physician, Steven Naifeh, Baylor University Medical Center, Alpha Omega Alpha, Rosacea, Patient, Saint Louis University, Baylor College of Medicine, Stanford University, Alpha and Omega, American Academy, Research, Nursing

DALLAS, Feb. 21, 2024 /PRNewswire/ -- Dallas Dermatology Partners proudly recognizes all five partners for being peer-selected among D Magazine's best dermatologists in Dallas for 2023.

Key Points: 
  • DALLAS, Feb. 21, 2024 /PRNewswire/ -- Dallas Dermatology Partners proudly recognizes all five partners for being peer-selected among D Magazine's best dermatologists in Dallas for 2023.
  • The final list is selected by their peers, who are other practicing physicians in Dallas, and represents the most "esteemed, exceptionally skilled, and compassionate" Dallas doctors.
  • Meet the Dallas Dermatology Partners included on this year's roster.
  • Dr. Melissa Costner holds the distinction among Dallas Dermatology Partners as the doctor with the longest record— 19 years — of being named among the area's "Best Doctors" list.

Michael F. Price Memorial Grant from the DeGregorio Family Foundation Awarded for Esophageal Cancer Research

Retrieved on: 
Wednesday, February 21, 2024
Stomach cancer, Neoplasm, De Gregorio, Doctor of Philosophy, MD, Immunotherapy, Esophageal cancer, Grant, Cancer, Mitochondrion, Associate, Patient, Protein, Baylor College of Medicine, Research, Mouse, Baylor University, Pharmaceutical industry

The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.

Key Points: 
  • The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.
  • Normally, the tumor cell 'energy center', called the mitochondria, protect the tumor cell from treatment with either chemotherapy or immunotherapy.
  • "The support of the DeGregorio Family Foundation is critical to the success of our research; we very much appreciate it," said Dr. Ripley.
  • The DeGregorio Family Foundation, founded in 2006 after a 10th member of the DeGregorio family died of stomach cancer, has raised more than $8 million to fund innovative research to cure gastric and esophageal cancers.

Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer

Retrieved on: 
Thursday, February 15, 2024
Oncology, Health, Neurology, Genetics, Pharmaceutical, Cardiology, Biotechnology, Alexion Pharmaceuticals, Ophthalmology, Indiana University, Metabolism, Rock, Growth, Diabetes, MBA, Allergan, Doctor of Philosophy, SMA, Genentech, Roche, University, Therapy, MPH, Medicine, American University, Baylor College of Medicine, Gongshi, Master of Science, Obesity, Research, Spinal muscular atrophy, Amgen, Management

“We are pleased to welcome Katie to Scholar Rock’s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,” said David Hallal, Chairman of the Board of Scholar Rock.

Key Points: 
  • “We are pleased to welcome Katie to Scholar Rock’s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,” said David Hallal, Chairman of the Board of Scholar Rock.
  • Katie joining our Board reflects the continued evolution of Scholar Rock, and as part of this process, Amir Nashat will be stepping down from the Board at this year’s annual shareholder meeting.
  • Prior to joining Denali, Ms. Peng managed a neurology, ophthalmology, immunology, and rare disease portfolio representing approximately $14 billion in revenue at Genentech.
  • “I am thrilled to join Scholar Rock’s Board of Directors as the company prepares for its first potential commercial launch of apitegromab.

Kemper Names Dr. Suzet McKinney of Sterling Bay to Board of Directors, Announces Retirement of Director Christopher Sarofim

Retrieved on: 
Wednesday, February 7, 2024
Professional Services, Insurance, Finance, Principal, Policy, Public, KMPR, MD Anderson Cancer Center, Brandeis University, Ecosystem, Public health, Advisory Committee, Organization, Kemper Corporation, Baylor College of Medicine, Wintrust Financial, Corporation, McKinney, Texas, Trustee, University, Benedictine University, Chicago school, Management

Kemper Corporation (NYSE: KMPR) announced that its Board of Directors has elected Dr. Suzet M. McKinney as a Director, effective February 7.

Key Points: 
  • Kemper Corporation (NYSE: KMPR) announced that its Board of Directors has elected Dr. Suzet M. McKinney as a Director, effective February 7.
  • The Board also announced that Christopher B. Sarofim has informed the Board of his intention to retire as a director at the end of his current term, expiring May 1, 2024.
  • Prior to Sterling Bay, she held a number of senior leadership roles in public health and policy administration.
  • “We’re pleased to welcome Suzet to our board,” said Joseph P. Lacher, Jr., President, CEO and Chairman of Kemper’s Board of Directors.

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Molecule, Royalty payment, Conference, Liver disease, Calendar, Breast, Immunotherapy, RCC, PIN, ASCO, NHT, Progression-free survival, Safety, FDA, PLK4, ADC, ITT, PKMYT1, Associate, University, Baylor University, PARP, USP1, Society, Neck, Science, Acquisition, Biology, Superior, Huntsman Cancer Institute, Dean (education), Metastasis, PFS, Translational research, Drug development, Distinguishing, Head, Food, NET, Baylor College of Medicine, Cancer, Share repurchase, BIRC, OS, SCCHN, Neoplasm, Congress, National Cancer Institute, Abbreviated New Drug Application, Research, Docetaxel, Translation, Prostate cancer, Therapy, ESMO, Education, Experiment, Checkmate, Pharmaceutical industry

In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.

Key Points: 
  • In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.
  • Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter and year ended December 31, 2023, Exelixis earned $40.7 million and $148.5 million, respectively, in royalty revenues.
  • In October 2023, detailed results were presented from the phase 3 CABINET pivotal trial at the 2023 ESMO Congress.
  • Exelixis management will discuss the company’s financial results for the fourth quarter and fiscal year of 2023 and provide a general business update during a conference call beginning at 5:00 p.m.

Baylor Genetics Chief Medical Officer Christine Eng, M.D., Shares Sequencing Approaches for Undiagnosed Patients at Precision Medicine World Conference 2024

Retrieved on: 
Tuesday, January 23, 2024
Silicon, Whole genome sequencing, M.D, Patient, DSM-IV codes, Harvard University, Intensive care medicine, NICU, Baylor College of Medicine, Gene, WGS, Blog, Genetics, WES, Genetic testing, PICU, Conference, NIH, Sequence, Genome, Clinical trial, Bangladesh Technical Education Board, Hall, Diagnosis, UDN

Eng’s presentation will focus on the groundbreaking work and clinical findings from the National Institutes of Health’s (NIH) Undiagnosed Diseases Network (UDN).

Key Points: 
  • Eng’s presentation will focus on the groundbreaking work and clinical findings from the National Institutes of Health’s (NIH) Undiagnosed Diseases Network (UDN).
  • Baylor Genetics and partner Baylor College of Medicine have served as the sole sequencing core for UDN since its inception in 2014, providing WGS/WES testing, interpretation, validation and reporting for patients with rare genetic diseases.
  • The Harvard Gazette recently published one such story, noted in a Baylor Genetics blog on navigating the maze of undiagnosed diseases.
  • Learn more about PMWC through the conference website and visit the Baylor Genetics website to explore the company’s full spectrum of genetic testing capabilities.

Texas Children's Announces Physician Leadership Team at North Austin Campus

Retrieved on: 
Thursday, January 25, 2024
Senior, Child, Woman, Stanford University, Rodale, Inc., Patient, Uterine fibroid, Texas Children's Hospital, Endometriosis, Chiari malformation, Neurology, DRS, Cardiology, Intervention, Gynaecology, Plastic, Hepatology, Baylor College of Medicine, PALS, Pediatrics, Baylor University, Strategic planning, Obstetrics and gynaecology, Medicine, Hospital, Service, Radiology, Rheumatology, Most, Gastroenterology, ERAS, Plastic surgery, American College, Physician, Nursing

"We are honored to bring such amazing talent to our hospital," said Russ Williams , Senior Vice President of Texas Children's North Austin Campus.

Key Points: 
  • "We are honored to bring such amazing talent to our hospital," said Russ Williams , Senior Vice President of Texas Children's North Austin Campus.
  • A past winner of the Most Valuable Physician award at St. David's South Austin Medical Center, she is thrilled to bring her expertise to Texas Children's Hospital North Austin.
  • With these new appointments, Texas Children's Hospital North Austin Campus is ready to expand that tradition of exceptional care for children and women in Austin."
  • Located at 9835 North Lake Creek Parkway, Texas Children's North Austin will connect patients and families to Texas Children's numerous subspecialties including cardiology, oncology, neurology, pulmonology, gastroenterology, rheumatology, fetal care and more.